Picture of Effector Therapeutics logo

EFTR Effector Therapeutics Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapValue Trap

Annual income statement for Effector Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSPROSPECTUS10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue0421.433.550
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses28.626.233.83633.8
Operating Profit-28.615.8-32.4-32.4-33.8
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-29.714.615.8-22.7-35.8
Provision for Income Taxes
Net Income After Taxes-29.714.215.8-22.7-35.8
Net Income Before Extraordinary Items
Net Income-29.714.215.8-22.7-35.8
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-14.20.16615.8-22.7-35.8
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-8.740.10210-13.8-16.4